We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$20B
AUM Growth
+$2.54B
Cap. Flow
+$128M
Cap. Flow %
0.64%
Top 10 Hldgs %
72.82%
Holding
92
New
8
Increased
16
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$276M
2
INSM icon
Insmed
INSM
+$166M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$32.6M
4
FTH
Faeth Therapeutics
FTH
+$29.8M
5
RLAY icon
Relay Therapeutics
RLAY
+$24.2M

Top Sells

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$99.1M
2
ABVX
Abivax
ABVX
+$97.5M
3
SMMT icon
Summit Therapeutics
SMMT
+$63.9M
4
SYRE icon
Spyre Therapeutics
SYRE
+$50.4M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$26.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GENB
51
Generate Biomedicines
GENB
$1.97B
$24M 0.12%
1,423,602
– –
DBVT
52
DBV Technologies
DBVT
$851M
$24M 0.12%
1,461,425
– –
XENE icon
53
Xenon Pharmaceuticals
XENE
$5.81B
$22.3M 0.11%
370,208
– –
TECX
54
Tectonic Therapeutic
TECX
$696M
$20.9M 0.1%
607,788
– –
CERS icon
55
Cerus
CERS
$534M
$18.7M 0.09%
6,395,431
-3,612,914
-36% -$8.76M
CTMX icon
56
CytomX Therapeutics
CTMX
$699M
$18.7M 0.09%
4,975,826
– –
DYN icon
57
Dyne Therapeutics
DYN
$4.68B
$18.1M 0.09%
813,449
– –
CYTK icon
58
Cytokinetics
CYTK
$10B
$18M 0.09%
+211,267
New +$15.2M
XNCR icon
59
Xencor
XNCR
$1.94B
$17.7M 0.09%
1,102,106
– –
SION
60
Sionna Therapeutics
SION
$265M
$17.6M 0.09%
400,000
– –
NTLA icon
61
Intellia Therapeutics
NTLA
$1.8B
$15.7M 0.08%
+930,232
New +$13M
PBLS
62
Parabilis Medicines Inc
PBLS
$4.83B
$13.7M 0.07%
+500,000
New +$13.8M
MPLT
63
MapLight Therapeutics
MPLT
$584M
$13.1M 0.07%
364,705
– –
AVLN
64
Avalyn Pharma
AVLN
$1.54B
$11.5M 0.06%
+350,000
New +$10.1M
EVMN
65
Evommune Inc
EVMN
$480M
$11.3M 0.06%
847,390
– –
BNTX icon
66
BioNTech
BNTX
$25.6B
$11.1M 0.06%
119,743
– –
TNGX icon
67
Tango Therapeutics
TNGX
$3.94B
$10.4M 0.05%
+333,333
New +$8.24M
AVTX icon
68
Avalo Therapeutics
AVTX
$1.05B
$10.2M 0.05%
+550,000
New +$8.69M
SERA icon
69
Sera Prognostics
SERA
$81.7M
$10M 0.05%
5,498,170
– –
VSTM icon
70
Verastem
VSTM
$654M
$9.55M 0.05%
2,499,338
+1,914,581
+327% +$9.26M
SGMT icon
71
Sagimet Biosciences
SGMT
$656M
$7.37M 0.04%
952,996
– –
EIKN
72
Eikon Therapeutics
EIKN
$595M
$7.25M 0.04%
555,555
– –
LBRX
73
LB Pharmaceuticals
LBRX
$1.54B
$6.49M 0.03%
200,000
– –
VTVT icon
74
vTv Therapeutics
VTVT
$128M
$5.58M 0.03%
148,314
– –
WVE icon
75
Wave Life Sciences
WVE
$993M
$4.78M 0.02%
822,638
– –
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Baker Bros. Advisors held 92 positions worth $20B, up 15% from $17.4B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors's Q2 2026 filing shows 8 new, 16 increased, 7 reduced and 9 closed positions. Its largest new stake was Faeth Therapeutics: 1,286,411 shares worth $32.2M. The largest sale was Edgewise Therapeutics, an estimated $99.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • Baker Bros. Advisors's largest Q2 2026 buy was Faeth Therapeutics: 1,286,411 shares worth $32.2M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q2 2026, an estimated $276M increase.
  • Baker Bros. Advisors's biggest Q2 2026 reduction was Edgewise Therapeutics, cutting an estimated $99.1M.
  • Baker Bros. Advisors fully exited Abivax in Q2 2026, selling an estimated $97.5M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $20B portfolio in Q2 2026.
  • Baker Bros. Advisors opened 8 new positions and closed 9 in Q2 2026.
  • Baker Bros. Advisors's portfolio value rose 15% quarter-over-quarter to $20B.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.